HCPCS Level II code C2616 denotes a non-stranded yttrium-90 brachytherapy source billed per individual source. This code captures the device component of internal radiation therapy used in targeted oncologic procedures and matters nationally because brachytherapy supply coding affects hospital and outpatient radiation oncology billing, inventory accounting, and payer coverage determinations for high-cost radioactive sources. Clarity on device coding supports consistent claims submission and payment for complex radiation treatments.

Key payers in the coverage analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how these payers commonly handle device and implant supply coding, and highlights national considerations for reimbursement policies and prior authorization practices where applicable.

Readers will learn the clinical and billing context for C2616, including the typical service setting (hospital outpatient departments and specialized radiation oncology clinics), the nature of the supply (individual, non-stranded yttrium-90 sources), and how this code fits into broader brachytherapy billing workflows. The report also summarizes available benchmarks, common payer coverage themes, and relevant policy updates or coding guidance when present. Data not available in the input is clearly noted where applicable.